The Ministry of Health has published a list of medicinal products that are not subject to financing under the Rescue Access to Drug Technology (RDTL) procedure. The Health Ministry assures that patients who started treatment before the list came into effect retain the right to continue therapy - under certain conditions.
Drugs without RDTLs. There's a new list
Published June 2, 2026 07:58
The MInisterium of Health website has published a communiqué from the Minister of Health with the latest list of medicinal products not subject to funding under the emergency procedure for access to drug technologies.
RDTL is a mechanism that allows public financing of therapies that are not covered by reimbursement, but which in individual cases may be the only available therapeutic option for the patient. Publication of the list means that the medicinal products indicated therein cannot be financed under this procedure.
At the same time, the Ministry of Health stresses that patients who started treatment with a listed medicinal product before the effective date of the list do not automatically lose access to therapy. Continuation of treatment is possible provided that the effectiveness of the treatment administered to date is proven.
In such cases, the provider is obliged to provide information on the continuation of treatment to the locally competent branch of the National Health Fund. Only compliance with this condition allows the continuation of funding for treatment started before the list came into force.
The list included 101 items.
Among the medicines that will not be subject to funding under the emergency procedure for access to drug technology (RDTL), according to a January 16, 2026 announcement from the Ministry of Health, are: Adynovi (rurioctocog alfa pegolum) for the prevention of bleeding in children under 12. age with hemophilia A and B, Afinitor (everolimus) for the treatment of advanced breast cancer, Aimovig (erenumab) for chronic migraine, Brineura (cerliponase alfa) for the treatment of neuronal lipofuscinosis type 2, Cresemba (isavuconazole) for invasive aspergillosis and mucormycosis, and three versions of the drug erlotinib (from Krka, Mylan and Vipharm) for non-small cell and small cell lung cancer. Also on the list are Lynparza (olaparib) for the treatment of endometrial cancer and pancreatic adenocarcinoma with a BRCA1/2 mutation, Rybrevant (amivantamab) for patients with advanced lung cancer with an EGFR insertion mutation in exon 20, Zolgensma (onasemnogene abeparvovecum) for the treatment of SMA in patients not covered by the drug program, and Yervoy (ipilimumab) in esophageal cancer and as monotherapy in melanoma in second-line treatment.
List: TU
Source: MZ
